The BRAIN Act is a comprehensive legislative package designed to advance research into brain tumor treatments and improve patient care and awareness. The bill addresses the stagnant progress in brain tumor treatment over the past 45 years, noting that glioblastoma—the most common malignant brain tumor—has only a 6.9 percent five-year survival rate. The legislation creates several key initiatives: it establishes a searchable, public database of brain tumor tissue samples funded by the National Institutes of Health to facilitate research transparency; establishes a $50 million per year (2026-2030) Glioblastoma Therapeutics Network to test new treatments; allocates $10 million annually (2026-2030) for cellular immunotherapy research including CAR-T treatments for brain tumors; and funds a $10 million national public awareness campaign to educate patients and healthcare providers about clinical trials and biomarker testing. Additionally, the bill provides $5 million per year (2026-2030) for pilot programs to develop better long-term care approaches for brain tumor survivors and directs the FDA to issue guidance within one year on expanding brain tumor patients' access to clinical trials. The legislation was introduced with bipartisan support in April 2025.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.